Abbott Laboratories vs Gilead Sciences

Abbott Laboratories (ABT), health care, and Gilead Sciences (GILD), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Gilead Sciences is worth $210.7B on the stock market and Abbott Laboratories $184.1B: Gilead Sciences is valued at 14% more. Abbott Laboratories's operating margin in its latest fiscal year was 18.2% and Gilead Sciences's 34.0%. Over the past year Abbott Laboratories's share price has moved -17.3% and Gilead Sciences's +31.8%.

Key facts

Abbott Laboratories market value
$184.1B
Gilead Sciences market value
$210.7B
Abbott Laboratories P/E
39.7
Abbott Laboratories revenue
$44.3BFY to 2025-12-31
Gilead Sciences revenue
$29.4BFY to 2025-12-31
Superinvestors holding both
3

Market values as of .

Abbott Laboratories vs Gilead Sciences: every measure side by side
Measure Abbott Laboratories Gilead Sciences
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$184.1Blower$210.7Bhigher
Revenue$44.3Bhigher$29.4Blower
Earnings$6.5Blower$8.5Bhigher
Employees122,000higher17,000lower
Total assets$86.7Bhigher$59Blower
Valuation
P/E39.7—
P/S4.2lower7.2higher
P/B3.6lower16.2higher
Dividend yield2.35%higher1.94%lower
Profitability
Operating margin18.2%lower34.0%higher
Balance sheet
Net assets$52.1Bhigher$22.7Blower
Total liabilities$33.9Blower$36.4Bhigher
Total debt$12.9Blower$24.9Bhigher
Cash on hand$8.5Bhigher$7.6Blower
Price change
Today-1.09%lower+1.39%higher
1 year-17.3%lower+31.8%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": Abbott Laboratories / Gilead Sciences). Who owns ABT · Who owns GILD

Further comparisons

Learn

Questions and answers

Which is bigger, Abbott Laboratories or Gilead Sciences?

By market value, Gilead Sciences is the larger: $210.7B against $184.1B for Abbott Laboratories. By revenue in its latest fiscal year, Abbott Laboratories is the larger: $44.3B against $29.4B for Gilead Sciences.

Which has the higher operating margin?

Gilead Sciences: 34.0%, against 18.2% for Abbott Laboratories. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Abbott Laboratories: 2.35%, against 1.94% for Gilead Sciences. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which has more debt?

Gilead Sciences: $24.9B, against $12.9B for Abbott Laboratories. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Abbott Laboratories and Gilead Sciences?

In their latest 13F filings, Brandon Haley, Ken Griffin and Steve Cohen hold both.

Cite this page

Funkfolio, “Abbott Laboratories vs Gilead Sciences”, data as of 17 November 2026. https://funkfolio.com/compare/abt-vs-gild

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.